CARBOGEN AMCIS

CARBOGEN AMCIS is a contract development and manufacturing organization (CDMO) serving the pharmaceutical and biopharmaceutical industries. The company describes its work as supporting customers at all stages of drug development, from development through commercialization. Its capabilities include chemical process research and development, active pharmaceutical ingredient (API) development and manufacturing, and drug-product services for preclinical studies, clinical trials, and commercial use. Its offerings span drug substance and sterile drug product. The company highlights experience in API development and manufacturing, injectable drug-product development and manufacturing, and production at scales ranging from grams to several thousand kilograms for APIs. Its website also reports API production capacity of up to 6,300 liters. In addition to contract services, CARBOGEN AMCIS offers cholesterol and vitamin D analog products made at its Netherlands facility, including products used in markets around the world. The company identifies itself as a member of the Dishman Carbogen Amcis Group and describes itself as Switzerland-based. Its website reports a global presence with eight sites in Switzerland, the United Kingdom, France, the Netherlands, and China. It emphasizes scientific capability, project collaboration, communication, quality, patient safety, regulatory support, and environmental responsibility. Its stated aim is to partner with customers to help bring drug projects from bench to market.

CARBOGEN AMCIS is a pharmaceutical and biopharmaceutical contract development and manufacturing organization. Its current website presents the business as a partner for drug development and commercialization, with services spanning chemical process research and development, API supply, and drug-product work. The available company material does not specify a founding date or founder, so those details are not included here. The company's service model covers multiple stages of pharmaceutical development. It describes capabilities for preclinical, clinical, and commercial use, including process development and API manufacturing as well as sterile drug-product development and manufacturing. Its website reports more than 40 years of experience in clinical API development, but the supplied material does not identify the date when that experience began. It also describes API production ranging from gram quantities to several thousand kilograms and reports capacity of up to 6,300 liters. CARBOGEN AMCIS also has a product activity alongside its contract services: it offers cholesterol and vitamin D analog products made at a facility in the Netherlands. The company says these products serve a variety of markets around the globe. The supplied sources do not provide a product launch chronology or identify specific product names. The company identifies itself as a member of the Dishman Carbogen Amcis Group. Its website describes CARBOGEN AMCIS as Switzerland-based and reports a global presence with eight sites in Switzerland, the United Kingdom, France, the Netherlands, and China. The available material does not give a complete site-by-site history or dates for geographic expansions. The company describes quality and patient safety as central to its operations. It says its API and drug-product facilities operate to current Good Manufacturing Practice (cGMP) standards, and notes that regulatory authorities and customers inspect its facilities. It also describes support functions including quality management, regulatory affairs, project management, environment, safety and health, and supply-chain management. Its quality page references ICH guidance and a phase-appropriate approach to patient safety. Recent company updates in the supplied homepage material report the commissioning of a ground-mounted photovoltaic plant at the Hunzenschwil site and a successful unannounced NMPA GMP inspection at the Shanghai site, with no observations identified. These updates reflect the company's stated attention to environmental performance and regulatory quality, but the supplied text does not provide dates for either event. Overall, the available evidence portrays CARBOGEN AMCIS as an active international CDMO whose services and specialty products support customers across pharmaceutical development and manufacturing.

A science-led, quality-focused CDMO partner supporting pharmaceutical and biopharmaceutical customers from drug development through commercialization, with services spanning drug substance and drug product.

• Drug-substance and API services

  Development and manufacturing services for active pharmaceutical ingredients, including process development.

• Sterile drug-product services

  Development and manufacturing services for injectable drug products.

• Cholesterol and vitamin D analog products

  Specialty products produced at the company's Netherlands facility.

• Renewable-energy investment at HunzenschwilOther

1. 1CARBOGEN AMCIS: CDMO Pharma | Pharmaceutical Contract Manufacturingcarbogen-amcis.com
2. 2About us: get to know CARBOGEN AMCIScarbogen-amcis.com
3. 3CDMO services - CDMO full-servicecarbogen-amcis.com
4. 4CDMO Quality services | Quality Managementcarbogen-amcis.com